Index

Note: Page numbers of article titles are in **boldface** type.

A	carotid
ACAC (Asymptometric Countied Athennes along in Chyrly)	endarterectomy for. See Carotid
ACAS (Asymptomatic Carotid Atherosclerosis Study),	endarterectomy.
449–450	stenting for, 447–458
ACST (Asymptomatic Carotid Surgery Trial),	intracranial, 434–439
449–450	angioplasty for, 435-436
ACTI (Asymptomatic Carotid Stenosis Stenting vs.	clinical impact of, 434-435
Endarterectomy Trial), 448	extracranial-intracranial bypass for, 480-481
Age factors, in intracerebral hemorrhage, 402	pathophysiology of, 435
AjVDO ₂ (arterial to jugular venous oxygen saturation),	pharmacologic therapy for, 435
perioperative monitoring of, 493–494	stenting for, 436–439
Alcohol consumption, intracerebral hemorrhage in, 403	Autoregulation, assessment of, 481, 492-493
Amphetamines, intracerebral hemorrhage due to,	
403	В
Amyloid angiopathy, 403	
Aneurysm(s), intracranial, 469-476	Barbiturates, for intracranial pressure reduction,
Charcot-Bouchard, 403	408–409
epidemiology of, 469-470	Basilar artery, dissection of, stenting for, 441
extracranial-intracranial bypass for, 477–479	BHP (British Heart Protection) study, 450
stenting for, 439–441	Blood flow, cerebral, perioperative monitoring of,
treatment options for, 470–474	490–492
Aneurysm Screening after Surgical Treatment for	Brain, hemorrhage of, intracerebral. See Intracerebral
Ruptured Aneurysms (ASTRA), 471	hemorrhage.
Angiography, computed tomography, in	Brain tissue oxygen tension, perioperative monitoring
intracerebral hemorrhage, 405-407	of, 494–495
Angiopathy, amyloid, 403	British Heart Protection (BHP) study, 450
Angioplasty	Bypass, extracranial-intracranial, 477–487
carotid, versus endarterectomy, 447-458	
intracranial, for atherosclerosis, 435-436	С
Antihypertensive drugs, for intracerebral	-
hemorrhage, 407-408, 415-416	CAPRIE (Clopidogrel versus Aspirin in Patients at
Antiplatelet therapy	Risk of Ischemic Events), 450
for stent use, 434	CARE (Carotid Artery Revascularization and
intracerebral hemorrhage due to, 403	Endarterectomy) registry, 448
Arterial to jugular venous oxygen saturation (AjVDO ₂),	Carotid and Vertebral Artery Transluminal
perioperative monitoring of, 493-494	Angioplasty Study (CAVATAS), 452-453, 455
Aspiration, of intracerebral hematoma, 418-420	Carotid artery
Aspirin	endarterectomy of. See Carotid endarterectomy.
for atherosclerotic disease, 435	sacrifice of, extracranial-intracranial bypass for,
for stent use, 434	477–479
ASTRA (Aneurysm Screening after Surgical	stenting of
Treatment for Ruptured Aneurysms), 471	clinical trials of, 452-455
Asymptomatic Carotid Atherosclerosis Study (ACAS),	technique for, 451–452
449–450	versus carotid endarterectomy, 447–458
Asymptomatic Carotid Stenosis Stenting vs.	Carotid Artery Revascularization and Endarterectomy
Endarterectomy Trial (ACTI), 448	(CARE) registry, 448
Asymptomatic Carotid Surgery Trial (ACST), 449–450	Carotid endarterectomy
Atherosclerosis	cerebral blood flow measurement during, 492

D

DECIMAL (decompressive craniectomy in malignant

middle cerebral artery infarcts), 462

Carotid (continued) Decompression, for middle cerebral artery infarction, clinical trials of, 447-451, 454-455 461-465 emergency, 429-430 Deoxyhemoglobin measurement, perioperative, post-stroke timing of, 425-432 495-497 historical background of, 425-426 DESTINY (Decompressive surgery for the treatment imaging for, 428-429 of malignant infarct of the middle cerebral artery), in emergency situation, 429-430 in mild stroke, 426-428 Dissections, intracranial, stenting for, 441 versus carotid stenting, 447-458 Doppler studies Carotid Occlusion Surgery Study (COSS), 480-481 in cerebral blood flow measurement, 491-492 Catheters for intracranial pressure monitoring, 489-490 in extracranial-intracranial bypass planning, for jugular venous oximetry, 493-494 480-481 for microdialysis, 497-498 Double-indicator dilution technique, for cerebral CAVATAS (Carotid and Vertebral Artery Transluminal blood flow measurement, 491 Angioplasty Study), 452-453 Drug-eluting stents, for intracranial disease, 434 Cerebellar artery, posterior inferior, for Durotomy and duroplasty, for middle cerebral artery extracranial-intracranial bypass, 483-485 infarction, 461-465 Cerebral artery, middle for extracranial-intracranial bypass, 478-481, 483 infarction of, 459-468 ECST (European Carotid Surgery Trial), 425, 428, 447 Cerebral blood flow, perioperative monitoring of, Edema, cerebral, in middle cerebral artery infarction, 490-492 459-465 Cerebral microdialysis, perioperative, 497–498 Encephaloduroarteriomyosynagiosis, for moyamoya Cerebrovascular reactivity, perioperative monitoring disease, 483 of. 492-493 Endarterectomy, carotid. See Carotid Charcot-Bouchard aneurysms, 403 endarterectomy. Clipping, of aneurysms, 470-474 Endarterectomy versus Stenting in Patients with Clopidogrel, for stent use, 434 Symptomatic Severe Carotid Stenosis (EVA-3S) Clopidogrel versus Aspirin in Patients at Risk of study, 447-448, 454 Ischemic Events (CAPRIE), 450 Endoscopic aspiration, of intracerebral hematoma, Clot Lysis Evaluating Accelerated Resolution of 418-419 Intra-Ventricular Hemorrhage, 418 Endovascular balloon occlusion test, in Coagulopathy, in intracerebral hemorrhage, extracranial-intracranial bypass planning, 410, 416 477-478 Cocaine use, intracerebral hemorrhage due to, 403 Enterprise microstent, for intracranial aneurysms, Coil treatment, of aneurysms, 470-474 440-441 Computed tomography Epidural catheter, for intracranial pressure in carotid endarterectomy planning, 428-429 monitoring, 489-490 in extracranial-intracranial bypass planning, 478, European Carotid Surgery Trial (ECST), 480-481 425, 428, 447 in intracerebral hemorrhage, 404-406 EVA-3S (Endarterectomy versus Stenting in Patients in middle cerebral artery infarction, 460 with Symptomatic Severe Carotid Stenosis) study, Computed tomography angiography, in intracerebral 447-448, 454 hemorrhage, 405-407 Extracranial-intracranial bypass, 477-487 Cordis Enterprise Vascular Reconstruction Device & for anterior circulation ischemia, 480-481 Delivery System, for intracranial aneurysms, for atherosclerosis, 480-481 440-441 for flow augmentation in ischemia, 480-485 COSS (Carotid Occlusion Surgery Study), 480-481 for flow replacement in planned vessel sacrifice, CREST (North American Carotid Revascularization 477-479 Endarterectomy versus Stenting Trial), 448, 454 for moyamoya disease, 482-483

for posterior circulation ischemia, 483-485

selective revascularization in, 477-479

universal revascularization in, 479

indications for, 477

strategies for, 478-479

F	risk factors for, 402–403
Factor VIII for introcerobral homographes 400, 410	secondary, 401–402
Factor VII, for intracerebral hemorrhage, 409–410, 417	treatment of, 415–423
	activated factor VII in, 409-410, 417
Fibrinolysis, of intracerebral hematoma, 419–420	acute, 407–410
Flowmetry methods, for cerebral blood flow measurement, 491	blood pressure control in, 407, 415-416
•	coagulopathy correction in, 410, 416
Furosemide, for intracranial pressure reduction, 408	fibrinolysis in, 419–420
	intracranial pressure reduction in, 407-409,
Н	416
HANALET (II	intraventricular thrombolysis in, 417–418
HAMLET (Hemicraniectomy After Middle cerebral	new approaches to, 417
artery infarction with Life-threatening Edema	resuscitation in, 415
Trial), 462	seizure control in, 416
HeADDFIRST (Hemicraniectomy and Durotomy on	surgical, 418-420
Deterioration from Infarction Related Swelling	volume of, 404
Trial), 461–462	Intracranial hypertension, benign/idiopathic, stenting
Hemicraniectomy, for middle cerebral artery	for, 441–442
infarction	Intracranial pressure
outcome of, 461–465	in cerebrovascular reactivity monitoring, 492–493
procedure for, 461	in intracerebral hemorrhage, 407–409, 416
syndrome of the trephined and, 465 Hemoglobin measurement, perioperative, 495–497	in middle cerebral artery infarction, 460–461
Hemophilia, intracerebral hemorrhage in, 409–410	perioperative, monitoring of, 489–490
Hemorrhage	Intraventricular catheter, for intracranial pressure
intracerebral. See Intracerebral hemorrhage.	monitoring, 489–490
subarachnoid, in aneurysms, 469–474	Intraventricular thrombolysis, for intracerebral
Hypercarbia, for intracranial pressure reduction, 408	hemorrhage, 417–418
Hypertension, intracerebral hemorrhage in, 402–403,	ISAT (International Subarachnoid Aneurysm Trial),
407–408, 415–416	470–474
Hyperventilation, for intracranial pressure reduction,	Ischemia
408, 416	extracranial-intracranial bypass for, 480–485
400, 410	perioperative monitoring of, 497–498
	ISUIA (International Study of Unruptured Intracranial
1	Aneurysms), 470–474
ICSS (International Carotid Stenting Study), 454	J
Indocyanine green, for cerebral blood flow	Japanese EC-IC Bypass Trial (JET), 480-481
measurement, 491	Joint Study of Extracranial Arterial Occlusion, 426
International Carotid Stenting Study (ICSS), 454	Jugular venous oximetry, perioperative, 493–494
International Study of Unruptured Intracranial	Sugular verious oximetry, perioperative, 493-494
Aneurysms (ISUIA), 470-474	
International Subarachnoid Aneurysm Trial (ISAT),	K
470–474	Kety-Schmidt method, for cerebral blood flow, 491
International Surgical Trial in Intracerebral	Kety-Schilliat Method, for Cerebral blood flow, 491
Haemorrhage, 410-411	
Intracerebral hemorrhage, 401–414	L
clinical features of, 404	
diagnosis of, 404–407	Laser Doppler flowmetry, for cerebral blood flow
distribution of, 402	measurement, 491
economic impact of, 401	Lipohyalinosis, 403
epidemiology of, 401–402	
hematoma expansion in, 409	M
mortality in, 401	
outcome of, 402	Magnetic resonance imaging
pathoetiology of, 402–403, 416–417	in extracranial-intracranial bypass planning,
pathophysiology of, 401–402	480–481
primary, 401–402	in intracerebral hemorrhage, 404-407

Magnetic (continued) in middle cerebral artery infarction, 460 Mannitol, for intracranial pressure reduction, 408,	Perindopril Protection Against Recurrent Stroke Study (PROGRESS), 450 Pipeline Neuroendovascular Device, for intracranial
416, 460–461 Microaneurysms, intracerebral hemorrhage in,	aneurysms, 439–441 Positron emission tomography,
403 Microdialysis, cerebral, perioperative, 497–498	in extracranial-intracranial bypass planning, 480–481
Microsensors, for intracranial pressure monitoring, 489–490	Postcraniotomy syndrome, 465 PROGRESS (Perindopril Protection Against
Middle cerebral artery infarction, 459–468 clinical manifestations of, 459	Recurrent Stroke Study), 450 Pseudotumor cerebri, stenting for, 441–442
mortality in, 459	PtiO ₂ (brain tissue oxygen tension), perioperative
outcome of, 459–460 pathophysiology of, 460	monitoring of, 494–495
prevalence of, 459	R
treatment of	
medical, 460–461 surgical, 461–465	Radioactive tracers, for cerebral blood flow measurement, 491
Minimally invasive surgery, for intracerebral	Resuscitation, for intracerebral hemorrhage,
hemorrhage, 411, 418-420	407–410, 415
Moyamoya disease, extracranial-intracranial bypass for, 482–483	Revascularization
101, 462–463	extracranial-intracranial bypass for, 477–487 for carotid artery disease. See also Carotid
	endarterectomy.
N	stenting in, 451-455
NASCET (North American Symptomatic Carotid	_
Endarterectomy Trial), 425–428, 448–450 Near infrared spectroscopy, for perioperative	S
monitoring, 495–497	SAMMPRIS (Stenting vs. Aggressive Medical
Neuroform microstent, for intracranial aneurysms, 440	Management for Preventing Recurrent Stroke in Intracranial Stenosis) trial, 438
Neurolink balloon-mounted stent, 437	SAPPHIRE (Stenting and Angioplasty with Protection
Nitroprusside test, in extracranial-intracranial bypass planning, 478	in Patients at High Risk for Endarterectomy) trial, 447–448, 453–455
Nitrous oxide, for cerebral blood flow measurement, 491	Sedation, for intracranial pressure reduction, 408–409
North American Carotid Revascularization	Seizures, in intracerebral hemorrhage, 416 Single photon emission computed tomography, in
Endarterectomy versus Stenting Trial (CREST), 448, 454	extracranial-intracranial bypass planning, 478,
North American Symptomatic Carotid	480–481
Endarterectomy Trial (NASCET), 425–428, 448–450	Sirolimus, stents eluting, 434, 439 SjVO ₂ (jugular oxygen saturation), perioperative monitoring of, 493–494
	SPACE (Stent-supported Percutaneous Angioplasty
0	of the Carotid Artery versus Endarterectomy)
Occipital artery, for extracranial-intracranial bypass,	study, 447–448, 455
483–485	SSYLVIA (Stenting of Symptomatic Atherosclerotic Lesions in the Vertebral or Intracranial Arteries)
Oxygenation, cerebral, perioperative monitoring of, 493–495	trial, 437 Stenting
Oxyhemoglobin measurement, perioperative,	carotid artery
495–497	clinical trials of, 452-455
	technique for, 451–452
P	versus carotid endarterectomy, 447–458 for intracranial disease, 433–435
Paclitaxel, stents eluting, 434, 439	aneurysmal, 439–441
Perfusion monitoring, transcranial, 489–502	atheromatous, 434–435

biologically active, 434, 439
clinical trials of, 437–438
complications of, 434
definition of, 433
direct, 434
dissection, 441
elective, 434
history of, 433, 436–437
limitations of, 434
materials used in, 433–434
pharmacotherapy with, 434–435
provisional, 434
technical considerations in, 433–434
venous occlusive, 441–442
ing and Angioplasty with Protection in Patie

Stenting and Angioplasty with Protection in Patients at High Risk for Endarterectomy (SAPPHIRE) trial, 447–448, 453–455

Stenting of Symptomatic Atherosclerotic Lesions in the Vertebral or Intracranial Arteries (SSYLVIA) trial, 437

Stenting vs. Aggressive Medical Management for Preventing Recurrent Stroke in Intracranial Stenosis (SAMMPRIS) trial, 438

Stent-supported Percutaneous Angioplasty of the Carotid Artery versus Endarterectomy (SPACE) trial, 447–448, 455

Stereotactic clot aspiration, for intracerebral hematoma, 419–420

Streptokinase, for intracerebral hematoma, 419–420 Stroke

carotid endarterectomy after, 425-432

in aneurysms, 469-476

in atherosclerotic disease, 434-439

in evolution, carotid endarterectomy for, 429–430 in intracerebral hemorrhage. See Intracerebral hemorrhage.

in middle cerebral artery infarction, **459–468** prevention of

angioplasty for, 435-436

carotid endarterectomy for. See Carotid endarterectomy.

extracranial-intracranial bypass for, **477–487** pharmacologic therapy for, 435

Subarachnoid hemorrhage, in aneurysms, 469–474 Sunken flap syndrome, in hemicraniectomy, 465 Syndrome of the trephined, in hemicraniectomy, 465

Т

Temporal artery, superficial for encephaloduroarteriomyosynagiosis, 483 for extracranial-intracranial bypass, 478–481, 483 Thermal diffusion flowmetry, for cerebral blood flow measurement, 491 Thermal dilution method, for cerebral blood flow measurement, 491

Thrombolytic therapy, for intracerebral hemorrhage, 417–420

Thrombosis, of stents, in intracranial disease, 434 Tissue plasminogen activator, for intracerebral hemorrhage, 418–420

Transcranial perfusion monitoring, **489–502** applications of, 489 devices for, 489 microdialysis in, 497–498 near infrared spectroscopy in, 495–497 of cerebral blood flow, 490–492 of cerebrovascular reactivity, 492–493 of intracranial pressure, 489–490 of oxygenation, 493–495

Transient ischemic attacks, crescendo, carotid endarterectomy for, 429–430

U

UK Prospective Diabetes Study, 450
Ultrasonography, transcranial, for cerebral blood flow measurement, 491–492
Urokinase, for intracerebral hematoma, 419–420

ν

Vasodilation, autoregulatory, assessment of, 481
Vasospasm, cerebral, cerebral blood flow
measurement during, 492

Venous occlusive disease, stenting for, 441–442 Ventricular catheter, for intracranial pressure monitoring, 489–490

Ventricular drain, for intracranial pressure reduction, 407–408

Vertebral artery, angioplasty of, 436

Vertebrobasilar disease, extracranial-intracranial bypass for, 483–485

Vertebrobasilar junction, angioplasty of, 436 Vitamin K, for warfarin reversal, in intracerebral hemorrhage, 410, 416

w

Warfarin, intracerebral hemorrhage due to, 410, 416
WingSpan device, for intracranial stenosis, 437–438

Χ

Xenon-133, for cerebral blood flow measurement, 491